溃疡性结肠炎达标治疗策略成本效果的微观模拟模型
该研究采用微观模拟模型,评估溃疡性结肠炎患者起始生物制剂或小分子抑制剂治疗时,基于症状、症状联合粪便钙卫蛋白及内镜的达标监测策略的成本效果。模型追踪10万例患者5年,支付意愿阈值为10万美元/QALY。结果显示症状联合生物标志物监测的QALY最高,但单纯症状监测在86%的场景中成本效果最优。
要点
- 症状联合粪便钙卫蛋白监测的QALY最高
- 单纯症状监测在86%场景中成本效果最优
- 内镜监测仅在治疗成本高且患者不愿结肠切除时占优
核心结论
- 症状联合生物标志物监测获得最高QALY估计,但单纯症状监测是实施达标治疗最具成本效果的策略。
研究设计与样本
- 微观模拟模型,追踪10万例溃疡性结肠炎患者5年,支付意愿阈值为10万美元/QALY。
- 比较三种达标监测策略:单纯症状(直肠出血)、症状联合粪便钙卫蛋白、内镜。
- 模型模拟32种治疗序贯算法,并执行概率敏感性分析(500样本、250试验)及1至3向微观模拟敏感性分析。
主要发现
- 症状联合生物标志物监测在所有治疗序贯算法中QALY估计最高。
- 单纯症状监测在86%的场景中成本效果最优,症状联合生物标志物监测占9%,内镜监测占5%。
- 结果对治疗成本、患者对结肠切除的意愿及内镜成本敏感。
- 当治疗成本高且患者不愿接受结肠切除时,内镜监测更受青睐。
关键数值与推荐
- 主要分析支付意愿阈值为10万美元/QALY。
- 概率敏感性分析采用500样本和250试验。
临床怎么用
- 对于接受生物制剂或小分子抑制剂的溃疡性结肠炎患者,达标治疗监测可优先考虑单纯症状监测以优化成本效果。
- 当治疗成本较高且患者强烈不愿接受结肠切除时,可考虑内镜监测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Little is known about the cost effectiveness of endoscopy or biomarker-based treat to target monitoring of patients with ulcerative colitis (UC). METHODS: We used a microsimulation model to identify the most cost effective treat to target monitoring strategy for patients with UC staring therapy with biologics or small molecule inhibitors. We assessed symptoms (rectal bleeding) alone, a combination of symptoms and a biomarker (fecal calprotectin), and endoscopy. Transition probabilities, costs, and quality-adjusted life year (QALY) estimates were derived from published estimates. The microsimulation model tracked an individual patient's disease course and treatment exposures to modify downstream treatment effectiveness, probabilities, and disease outcomes. The primary analysis included 100,000 individuals over 5 years with a willingness to pay threshold of $100,000/QALY. Probabilistic sensitivity analyses were performed with 500 samples and 250 trials, in addition to multiple 1-, 2-, and 3-way microsimulation sensitivity analyses. RESULTS: A total of 32 treatment sequencing algorithms were modeled alongside 3 disease monitoring strategies within a treat to target approach for UC. Combination symptom and biomarker-based monitoring resulted in the highest QALY estimate among all the treatment sequencing algorithms. However, monitoring disease activity with symptoms alone was the most cost-effective strategy in 86% of scenarios, followed by combination symptom and biomarker monitoring in 9%, and endoscopy monitoring in 5%. Results were sensitive to treatment costs, patient willingness to consider colectomy as a treatment option, and endoscopy costs. Endoscopy-based monitoring was favored when treatment costs were high and patients were unwilling to undergo colectomy. CONCLUSIONS: The combination symptom and biomarker-based monitoring resulted in the highest QALY estimate. However, symptom-based monitoring is the most cost-effective approach to implementing treat to target monitoring for patients with UC receiving biologics and small molecule inhibitors.
引用
- Dulai PS, Sandborn WJ, Murphy J, et al. Microsimulation Model to Determine the Cost-Effectiveness of Treat-to-Target Strategies for Ulcerative Colitis. Clin Gastroenterol Hepatol. 2020. PMID: 32437872. doi:10.1016/j.cgh.2020.05.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。